Constipation Symptoms in Multiple System Atrophy Using Rome Criteria and Their Impact on Personalized Medicine
Abstract
:1. Introduction
2. Methods
2.1. Participants and Ethical Standards
2.2. Data Analysis
3. Results
3.1. Patient Characteristics
3.2. Characteristics of Constipation in MSA Patients
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Winge, K.; Rasmussen, D.; Werdelin, L.M. Constipation in neurological diseases. J. Neurol. Neurosurg. Psychiatry 2003, 74, 13–19. [Google Scholar] [CrossRef] [PubMed]
- Pellegrini, C.; Antonioli, L.; Colucci, R.; Ballabeni, V.; Barocelli, E.; Bernardini, N.; Blandizzi, C.; Fornai, M. Gastric motor dysfunctions in Parkinson’s disease: Current pre-clinical evidence. Parkinsonism Relat. Disord. 2015, 21, 1407–1414. [Google Scholar] [CrossRef] [PubMed]
- Mozaffari, S.; Nikfar, S.; Daniali, M.; Abdollahi, M. The pharmacological management of constipation in patients with Parkinson’s disease: A much-needed relief. Expert Opin. Pharmacother. 2020, 21, 701–707. [Google Scholar] [CrossRef] [PubMed]
- Mishima, T.; Fukae, J.; Fujioka, S.; Inoue, K.; Tsuboi, Y. The Prevalence of Constipation and Irritable Bowel Syndrome in Parkinson’s Disease Patients According to Rome III Diagnostic Criteria. J. Parkinsons Dis. 2017, 7, 353–357. [Google Scholar] [CrossRef] [Green Version]
- Drossman, D.A. Rome III: The new criteria. Chin. J. Dig. Dis. 2006, 7, 181–185. [Google Scholar] [CrossRef]
- Drossman, D.A.; Dumitrascu, D.L. Rome III: New standard for functional gastrointestinal disorders. J. Gastrointest. Liver Dis. 2006, 15, 237–241. [Google Scholar]
- Palma, J.A.; Kaufmann, H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov. Disord. 2018, 33, 372–390. [Google Scholar] [CrossRef]
- Gilman, S.; Wenning, G.K.; Low, P.A.; Brooks, D.J.; Mathias, C.J.; Trojanowski, J.Q. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 7, 670–676. [Google Scholar] [CrossRef]
- Koga, S.; Dickson, D.W. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 2018, 89, 175–184. [Google Scholar] [CrossRef]
- Ogura, H.; Hatip-Al-Khatib, I.; Suenaga, M.; Hatip, F.B.; Mishima, T.; Fujioka, S.; Ouma, S.; Matsunaga, Y.; Tsuboi, Y. Circulatory 25(OH)D and 1,25(OH) 2 D as differential biomarkers between multiple system atrophy and Parkinson’s disease patients. eNeurologicalSci 2021, 25, 100369. [Google Scholar] [CrossRef]
- Mathias, C.J. Gastrointestinal dysfunction in multiple system atrophy. Semin. Neurol. 1996, 16, 251–258. [Google Scholar] [CrossRef] [PubMed]
- Sakakibara, R.; Panicker, J.; Finazzi-Agro, E.; Iacovelli, V.; Bruschini, H.; Parkinson’s Disease Subcomittee, The Neurourology Promotion Committee in The International Continence Society. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol. Urodyn. 2016, 35, 551–563. [Google Scholar] [CrossRef] [PubMed]
- Vichayanrat, E.; Hentzen, C.; Batla, A.; Simeoni, S.; Iodice, V.; Panicker, J.N. Lower urinary tract dysfunction in Parkinsonian syndromes. Neurol. Sci. 2021, 42, 4045–4054. [Google Scholar] [CrossRef] [PubMed]
- Fukudo, S.; Hongo, M.; Matsueda, K. Rome III: The Functional Gastrointestinal Disorders: Japanese Version; KYOWA KIKAKU: Tokyo, Japan, 2008; pp. 306–326. [Google Scholar]
- Tomlinson, C.L.; Stowe, R.; Patel, S.; Rick, C.; Gray, R.; Clarke, C.E. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord. 2010, 25, 2649–2653. [Google Scholar] [CrossRef]
- Park, H.; Lee, J.Y.; Shin, C.M.; Kim, J.M.; Kim, T.J.; Kim, J.W. Characterization of gastrointestinal disorders in patients with parkinsonian syndromes. Parkinsonism Relat. Disord. 2015, 21, 455–460. [Google Scholar] [CrossRef]
- Schmidt, C.; Herting, B.; Prieur, S.; Junghanns, S.; Schweitzer, K.; Globas, C.; Schöls, L.; Reichmann, H.; Berg, D.; Ziemssen, T. Autonomic dysfunction in different subtypes of multiple system atrophy. Mov. Disord. 2008, 23, 1766–1772. [Google Scholar] [CrossRef]
- Sakakibara, R.; Odaka, T.; Uchiyama, T.; Liu, R.; Asahina, M.; Yamaguchi, K.; Yamaguchi, T.; Yamanishi, T.; Hattori, T. Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy. Mov. Disord. 2004, 19, 924–929. [Google Scholar] [CrossRef]
- Sakakibara, R. Gastrointestinal dysfunction in movement disorders. Neurol. Sci. 2021, 42, 1355–1365. [Google Scholar] [CrossRef]
- Zhang, X.; Svn, Z.; Liv, M.; Yang, Y.; Zeng, R.; Huang, Q.; Sun, Q. Association between irritable bowel syndrome and risk of Parkinson’s Disease: A systematic review and meta-analysis. Front. Neurol. 2021, 12, 720958. [Google Scholar] [CrossRef]
- Lu, S.; Jiang, H.Y.; Shi, Y.D. Association between irritable bowel syndrome and Parkinson’s disease: A systematic review and meta-analysis. Acta Neurol. Scand. 2021, in press. [CrossRef]
- Ishida, C.; Takahashi, K.; Kato-Motozaki, Y.; Tagami, A.; Komai, K. Effectiveness of Levodopa in Patients with Multiple System Atrophy and Associated Clinicopathological Features. Intern. Med. 2021, 60, 367–372. [Google Scholar] [CrossRef]
- Li, Z.S.; Schmauss, C.; Cuenca, A.; Ratcliffe, E.; Gershon, M.D. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: Analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. J. Neurosci. 2006, 26, 2798–2807. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nishiwaki, H.; Ito, M.; Ishida, T.; Hamaguchi, T.; Maeda, T.; Kashihara, K.; Tsuboi, Y.; Ueyama, J.; Shimamura, T.; Mori, H.; et al. Meta-Analysis of Gut Dysbiosis in Parkinson’s Disease. Mov. Disord. 2020, 35, 1626–1635. [Google Scholar] [CrossRef] [PubMed]
- Romano, S.; Savva, G.M.; Bedarf, J.R.; Charles, I.G.; Hildebrand, F.; Narbad, A. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021, 7, 27. [Google Scholar] [CrossRef]
- Shen, T.; Yue, Y.; He, T.; Huang, C.; Qu, B.; Lv, W.; Lai, H.Y. The Association Between the Gut Microbiota and Parkinson’s Disease, a Meta-Analysis. Front. Aging Neurosci. 2021, 13, 636545. [Google Scholar] [CrossRef]
- Toh, T.S.; Chong, C.W.; Lim, S.Y.; Bowman, J.; Cirstea, M.; Lin, C.H.; Chen, C.C.; Appel-Cresswell, S.; Finlay, B.B.; Tan, A.H. Gut microbiome in Parkinson’s disease: New insights from meta-analysis. Parkinsonism Relat. Disord. 2021, 94, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Pozuelo, M.; Panda, S.; Santiago, A.; Mendez, S.; Accarino, A.; Santos, J.; Guarner, F.; Azpiroz, F.; Manichanh, C. Reduction of butyrate- and methane-producing microorganisms in patients with Irritable bowel syndrome. Sci. Rep. 2015, 5, 12693. [Google Scholar] [CrossRef] [Green Version]
- Tana, C.; Umesaki, Y.; Imaoka, A.; Handa, T.; Kanazawa, M.; Fukudo, S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol. Motil. 2010, 22, 512–519. [Google Scholar] [CrossRef]
- Abbott, R.D.; Petrovitch, H.; White, L.R.; Masaki, K.H.; Tanner, C.M.; Curb, J.D.; Grandinetti, A.; Blanchette, P.L.; Popper, J.S.; Ross, G.W. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001, 57, 456–462. [Google Scholar] [CrossRef]
- Ueki, A.; Otsuka, M. Life style risks of Parkinson’s disease: Association between decreased water intake and constipation. J. Neurol. 2004, 251 (Suppl. S7), 18–23. [Google Scholar] [CrossRef]
- Astarloa, R.; Mena, M.A.; Sánchez, V.; de la Vega, L.; de Yébenes, J.G. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin. Neuropharmacol. 1992, 15, 375–380. [Google Scholar] [CrossRef] [PubMed]
- Cassani, E.; Privitera, G.; Pezzoli, G.; Pusani, C.; Madio, C.; Iorio, L.; Barichella, M. Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol. Dietol. 2011, 57, 117–121. [Google Scholar] [PubMed]
- Pagano, G.; Tan, E.E.; Haider, J.M.; Bautista, A.; Tagliati, M. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson’s disease. Parkinsonism Relat. Disord. 2015, 21, 120–125. [Google Scholar] [CrossRef]
- Lai, S.W.; Liao, K.F.; Lin, C.L.; Sung, F.C. Irritable bowel syndrome correlates with increased risk of Parkinson’s disease in Taiwan. Eur. J. Epidemiol. 2014, 29, 57–62. [Google Scholar] [CrossRef]
- Sakakibara, R.; Uchiyama, T.; Yamanishi, T.; Shirai, K.; Hattori, T. Bladder and bowel dysfunction in Parkinson’s disease. J. Neural Transm. 2008, 115, 443–460. [Google Scholar] [CrossRef]
- Simren, M.; Palsson, O.S.; Whitehead, W.E. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr. Gastroenterol. Rep. 2017, 19, 15. [Google Scholar] [CrossRef] [Green Version]
- Zhang, L.; Cao, B.; Ou, R.; Wei, Q.Q.; Zhao, B.; Yang, J.; Wu, Y.; Shang, H. Non-motor symptoms and the quality of life in multiple system atrophy with different subtypes. Parkinsonism Relat. Disord. 2017, 35, 63–68. [Google Scholar] [CrossRef]
Patients without Constipation (n = 22) | Patients with Constipation (n = 29) | p Value | |
---|---|---|---|
Age (years) | 65.3 ± 9.5 | 65.2 ± 11.1 | 0.434 |
Male (%) | 40.9 | 56.5 | 0.503 |
Disease duration (years) | 4.0 ± 2.7 | 4.9 ± 3.3 | 0.328 |
MMSE | 26.6 ± 3.6 | 26.9 ± 2.5 | 0.718 |
LED (mg/day) | 189.8 ± 344.3 | 244.3 ± 284.8 | 0.497 |
Laxative use (%) | 22.7 | 55.2 | 0.019 |
Anti-cholinergic use (%) | 0 | 0 | n.s. |
Question Items | Frequency (%) | OR | 95% CI |
---|---|---|---|
Straining | 61.9 | 2.404 | 0.575–10.040 |
Lumpy or hard stools | 47.0 | 2.775 | 0.668–11.532 |
Sensation of incomplete evacuation | 51.0 | 7.377 | 1.402–38.817 |
Sensation of anorectal obstruction | 68.6 | 2.462 | 0.583–10.398 |
Manual maneuvers | 13.7 | Not calculated | Not calculated |
Fewer defecations | 33.3 | 3.473 | 0.615–19.616 |
r | p Value | 95% CI | |
---|---|---|---|
Age (years) | 0.035 | 0.809 | −0.252–0.321 |
Disease duration (years) | 0.205 | 0.149 | −0.066–0.477 |
MMSE | −0.124 | 0.387 | −0.430–0.182 |
LED (mg/day) | 0.370 | 0.008 | 0.138–0.602 |
MSA-C (n = 22) | MSA-P (n = 29) | p Value | |
---|---|---|---|
Age (years) | 63.4 ± 10.8 | 67.0 ± 9.6 | 0.505 |
Male (%) | 36.3 | 48.3 | 0.569 |
Disease duration (years) | 4.6 ± 3.3 | 4.3 ± 2.8 | 0.466 |
MMSE | 27.3 ± 2.7 | 26.4 ± 3.2 | 0.956 |
LED (mg/day) | 40.9 ± 140.3 | 377.1 ± 326.2 | 0.032 |
Laxative use (%) | 18.2 | 62.0 | 0.002 |
MSA-C (n = 22) | MSA-P (n = 29) | p Value | |
---|---|---|---|
Constipation (%) | 40.9 | 69.0 | 0.045 |
Straining (%) | 50.0 | 72.4 | 0.101 |
Lumpy or hard stools (%) | 36.4 | 55.2 | 0.183 |
Sensation of incomplete evacuation (%) | 31.8 | 65.5 | 0.017 |
Sensation of anorectal obstruction (%) | 50.0 | 82.8 | 0.013 |
Manual maneuvers (%) | 9.1 | 17.2 | 0.402 |
Fewer defecations (%) | 18.2 | 44.8 | 0.046 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mishima, T.; Fujioka, S.; Kawazoe, M.; Inoue, K.; Arima, H.; Tsuboi, Y. Constipation Symptoms in Multiple System Atrophy Using Rome Criteria and Their Impact on Personalized Medicine. J. Pers. Med. 2022, 12, 838. https://doi.org/10.3390/jpm12050838
Mishima T, Fujioka S, Kawazoe M, Inoue K, Arima H, Tsuboi Y. Constipation Symptoms in Multiple System Atrophy Using Rome Criteria and Their Impact on Personalized Medicine. Journal of Personalized Medicine. 2022; 12(5):838. https://doi.org/10.3390/jpm12050838
Chicago/Turabian StyleMishima, Takayasu, Shinsuke Fujioka, Miki Kawazoe, Kotoe Inoue, Hisatomi Arima, and Yoshio Tsuboi. 2022. "Constipation Symptoms in Multiple System Atrophy Using Rome Criteria and Their Impact on Personalized Medicine" Journal of Personalized Medicine 12, no. 5: 838. https://doi.org/10.3390/jpm12050838